Pair page
Cagrilintide with Pramlintide
Mechanism-tag overlap and published literature for Cagrilintide and Pramlintide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
long-acting-amylin-analog
synthetic-amylin-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Cagrilintide and Pramlintide have published these mechanism-level observations. Not a co-administration recommendation.
Cagrilintide is the weekly long-acting successor in the same amylin-agonist class. Not used together with pramlintide (duplicative mechanism). Patients switching from pramlintide to cagrilintide (when commercially available and appropriate) benefit from weekly vs 3x-daily dosing.
Quick facts
Cagrilintide
Pramlintide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| — | Cagrilintide | ClinicalTrials.gov. REDEFINE 1 (NCT05567796) and REDEFINE 2 (NCT05394519). Novo Nordisk CagriSema Phase 3 program. | human trial, Phase 3 |
| 2023 | Cagrilintide | Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. | human trial, Phase 2 |
| 2023 | Cagrilintide | Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. (Comparator.) PMID 37366315 | human trial, Phase 2 |
| 2021 | Cagrilintide | Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. | human trial, Phase 2 |
| 2025 | Cagrilintide | Garvey WT, Frias JP, Jastreboff AM, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025. DOI: 10.1056/NEJMoa2502081. | human trial |
| 2025 | Cagrilintide | Davies MJ, Frias JP, Jastreboff AM, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2). N Engl J Med. 2025. PMID: 40544432. DOI: 10.1056/NEJMoa2502082. PMID 40544432 | human trial |
| 2022 | Cagrilintide | Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (Comparator.) PMID 35658024 | human trial |
| 2021 | Cagrilintide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. (Comparator.) PMID 33567185 | human trial |
| 2025 | Cagrilintide | Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025. (Novo Nordisk next-generation successor to CagriSema.) | human trial, Phase 1 |
| 2021 | Cagrilintide | Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286)… PMID 33894838 | human trial, Phase 1 |
| 2018 | Cagrilintide | Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25. Br J Pharmacol. 2018;175(1):3-17. PMID: 29059473. PMID 29059473 | review |
| 2021 | Cagrilintide | Kruse T, Dahl K, Frigeri P, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. Endocrinology. 2021;162(6):bqab057. PMID: 33727283. PMID 33727283 | research article |
| 2002 | Pramlintide | Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25(4):724-730. PMID: 119… PMID 11919131 | human trial, Phase 3 |
| 2021 | Pramlintide | Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and act… PMID 34798060 | human trial, Phase 2 |
| 2007 | Pramlintide | Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Me… PMID 17504894 | human trial, Phase 2 |
| 2004 | Pramlintide | Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Me… PMID 15498087 | human trial |
| 2003 | Pramlintide | Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):7… PMID 12610038 | human trial |
| 2021 | Pramlintide | Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, ph… PMID 33894204 | human trial, Phase 1 |
| 2007 | Pramlintide | Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30(11):2794-2799. PMID: 17698608. PMID 17698608 | human study |
| 2026 | Pramlintide | US Food and Drug Administration. Symlin (pramlintide acetate) injection prescribing information. AstraZeneca Pharmaceuticals. Current version accessed April 2026. | regulatory / registry |
| 2015 | Pramlintide | Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67(3):564-600. PMID: 26071095. (Comprehensive amylin pharmacology review.) PMID 26071095 | research article |
| 2008 | Pramlintide | Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816-1823. PMID: 18753666. PMID 18753666 | research article |
| 2005 | Pramlintide | Young A. Amylin: Physiology and Pharmacology. Adv Pharmacol. 2005;52:1-272. PMID: 16180321. (Comprehensive pharmacology review covering pramlintide development context.) PMID 16180321 | research article |
| 2002 | Pramlintide | Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther… PMID 12017420 | research article |
Related pair pages
More research context
Frequently asked
Have Cagrilintide and Pramlintide been studied together?
Researchers have published mechanistic-level co-administration discussion of Cagrilintide and Pramlintide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Cagrilintide and Pramlintide share?
Cagrilintide and Pramlintide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Cagrilintide and Pramlintide?
Cagrilintide: Investigational; CagriSema under review. Pramlintide: Approved 2005 (T1D + T2D). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Cagrilintide and Pramlintide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Cagrilintide profile and the Pramlintide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026